Literature DB >> 30725480

Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort.

Nur Zeinomar1, Kelly-Anne Phillips2,3,4, Mary B Daly5, Roger L Milne2,6, Gillian S Dite2, Robert J MacInnis2,6, Yuyan Liao1, Rebecca D Kehm1, Julia A Knight7,8, Melissa C Southey9, Wendy K Chung10,11, Graham G Giles2,6, Sue-Anne McLachlan12,13, Michael L Friedlander14,15, Prue C Weideman2, Gord Glendon7, Stephanie Nesci3, Irene L Andrulis7,16, Saundra S Buys17, Esther M John18, John L Hopper2, Mary Beth Terry1,10.   

Abstract

Benign breast disease (BBD) is an established breast cancer (BC) risk factor, but it is unclear whether the magnitude of the association applies to women at familial or genetic risk. This information is needed to improve BC risk assessment in clinical settings. Using the Prospective Family Study Cohort, we used Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association of BBD with BC risk. We also examined whether the association with BBD differed by underlying familial risk profile (FRP), calculated using absolute risk estimates from the Breast Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) model. During 176,756 person-years of follow-up (median: 10.9 years, maximum: 23.7) of 17,154 women unaffected with BC at baseline, we observed 968 incident cases of BC. A total of 4,704 (27%) women reported a history of BBD diagnosis at baseline. A history of BBD was associated with a greater risk of BC: HR = 1.31 (95% CI: 1.14-1.50), and did not differ by underlying FRP, with HRs of 1.35 (95% CI: 1.11-1.65), 1.26 (95% CI: 1.00-1.60), and 1.40 (95% CI: 1.01-1.93), for categories of full-lifetime BOADICEA score <20%, 20 to <35%, ≥35%, respectively. There was no difference in the association for women with BRCA1 mutations (HR: 1.64; 95% CI: 1.04-2.58), women with BRCA2 mutations (HR: 1.34; 95% CI: 0.78-2.3) or for women without a known BRCA1 or BRCA2 mutation (HR: 1.31; 95% CI: 1.13-1.53) (pinteraction  = 0.95). Women with a history of BBD have an increased risk of BC that is independent of, and multiplies, their underlying familial and genetic risk.
© 2019 UICC.

Entities:  

Keywords:  Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm; benign breast disease; breast cancer; familial risk

Mesh:

Substances:

Year:  2019        PMID: 30725480      PMCID: PMC6525034          DOI: 10.1002/ijc.32112

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  32 in total

1.  Clinicopathologic features of breast cancers that develop in women with previous benign breast disease.

Authors:  Daniel W Visscher; Marlene H Frost; Lynn C Hartmann; Ryan D Frank; Robert A Vierkant; Ann E McCullough; Stacey J Winham; Celine M Vachon; Karthik Ghosh; Kathleen R Brandt; Ann M Farrell; Yaman Tarabishy; Tina J Hieken; Tufia C Haddad; Ruth A Kraft; Derek C Radisky; Amy C Degnim
Journal:  Cancer       Date:  2015-10-29       Impact factor: 6.860

2.  Breast cancer incidence in a cohort of women with benign breast disease from a multiethnic, primary health care population.

Authors:  Maria J Worsham; Judith Abrams; Usha Raju; Alissa Kapke; Mei Lu; Jingfang Cheng; Donna Mott; Sandra R Wolman
Journal:  Breast J       Date:  2007 Mar-Apr       Impact factor: 2.431

3.  A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer.

Authors:  Geoffrey C Kabat; Joan G Jones; Neal Olson; Abdissa Negassa; Catherine Duggan; Mindy Ginsberg; Rita A Kandel; Andrew G Glass; Thomas E Rohan
Journal:  Cancer Causes Control       Date:  2010-01-19       Impact factor: 2.506

4.  BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research.

Authors:  Susan L Neuhausen; Hilmi Ozcelik; Melissa C Southey; Esther M John; Andrew K Godwin; Wendy Chung; Jeniffer Iriondo-Perez; Alexander Miron; Regina M Santella; Alice Whittemore; Irene L Andrulis; Saundra S Buys; Mary B Daly; John L Hopper; Daniela Seminara; Ruby T Senie; Mary Beth Terry
Journal:  Breast Cancer Res Treat       Date:  2008-08-14       Impact factor: 4.872

Review 5.  Breast cancer risk associated with proliferative breast disease and atypical hyperplasia.

Authors:  W D Dupont; F F Parl; W H Hartmann; L A Brinton; A C Winfield; J A Worrell; P A Schuyler; W D Plummer
Journal:  Cancer       Date:  1993-02-15       Impact factor: 6.860

6.  Evaluation of 2 breast cancer risk models in a benign breast disease cohort.

Authors:  Ryan D Frank; Stacey J Winham; Robert A Vierkant; Marlene H Frost; Derek C Radisky; Karthik Ghosh; Kathleen R Brandt; Mark E Sherman; Daniel W Visscher; Lynn C Hartmann; Amy C Degnim; Celine M Vachon
Journal:  Cancer       Date:  2018-06-22       Impact factor: 6.860

7.  Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease.

Authors:  Xuefen Su; Graham A Colditz; Walter C Willett; Laura C Collins; Stuart J Schnitt; James L Connolly; Michael N Pollak; Bernard Rosner; Rulla M Tamimi
Journal:  Int J Cancer       Date:  2010-01-01       Impact factor: 7.396

8.  Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource.

Authors:  Graham J Mann; Heather Thorne; Rosemary L Balleine; Phyllis N Butow; Christine L Clarke; Edward Edkins; Gerda M Evans; Sián Fereday; Eric Haan; Michael Gattas; Graham G Giles; Jack Goldblatt; John L Hopper; Judy Kirk; Jennifer A Leary; Geoffrey Lindeman; Eveline Niedermayr; Kelly-Anne Phillips; Sandra Picken; Gulietta M Pupo; Christobel Saunders; Clare L Scott; Amanda B Spurdle; Graeme Suthers; Kathy Tucker; Georgia Chenevix-Trench
Journal:  Breast Cancer Res       Date:  2006-02-13       Impact factor: 6.466

9.  Risk of breast cancer in Japanese women with benign breast disease.

Authors:  Y Minami; N Ohuchi; Y Taeda; A Takano; A Fukao; S Satomi; S Hisamichi
Journal:  Jpn J Cancer Res       Date:  1999-06

10.  The BOADICEA model of genetic susceptibility to breast and ovarian cancer.

Authors:  A C Antoniou; P P D Pharoah; P Smith; D F Easton
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

View more
  4 in total

1.  A Multicentre Observational Study on Risk Factors for Breast Cancer.

Authors:  Suvarna Khadilkar; Mounika Bopanna; Pallavi Parab; Seema Gulia; Sandhya Chhasatia; Sarita Kothari; Sajana Gogineni; Tarini Taneja; Prema Perumal; Dinesh Jethwa; Yogesh Kembhavi; Sudeep Gupta
Journal:  J Obstet Gynaecol India       Date:  2020-07-10

2.  Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC).

Authors:  Nur Zeinomar; Julia A Knight; Jeanine M Genkinger; Kelly-Anne Phillips; Mary B Daly; Roger L Milne; Gillian S Dite; Rebecca D Kehm; Yuyan Liao; Melissa C Southey; Wendy K Chung; Graham G Giles; Sue-Anne McLachlan; Michael L Friedlander; Prue C Weideman; Gord Glendon; Stephanie Nesci; Irene L Andrulis; Saundra S Buys; Esther M John; Robert J MacInnis; John L Hopper; Mary Beth Terry
Journal:  Breast Cancer Res       Date:  2019-11-28       Impact factor: 6.466

3.  Precise, Genotype-First Breast Cancer Prevention: Experience With Transferring Monogenic Findings From a Population Biobank to the Clinical Setting.

Authors:  Hannes Jürgens; Laura Roht; Liis Leitsalu; Margit Nõukas; Marili Palover; Tiit Nikopensius; Anu Reigo; Mart Kals; Kersti Kallak; Riina Kütner; Kai Budrikas; Saskia Kuusk; Vahur Valvere; Piret Laidre; Kadri Toome; Kadri Rekker; Mikk Tooming; Tiina Kahre; Krista Kruuv-Käo; Katrin Õunap; Peeter Padrik; Andres Metspalu; Tõnu Esko; Krista Fischer; Neeme Tõnisson
Journal:  Front Genet       Date:  2022-07-22       Impact factor: 4.772

4.  Commentary: No multiplicative GXE interactions for breast cancer risk: Have we reached a verdict or is the jury still out?

Authors:  Mary Beth Terry
Journal:  Int J Epidemiol       Date:  2020-02-01       Impact factor: 7.196

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.